ट्रेड Vir Biotechnology VIR

बेचें
 खरीदें

VirBiotechnology लाइव चार्ट

5m 15m 30m 1h 4h 1d 1w

उपकरण मूल बातें

Weekly Search
Weekly
Daily
दिनांक बंद करें परिवर्तन (%) परिवर्तित करें खुला उच्च कम

VirBiotechnology news

नवीनतम समाचार

और दिखाएं
Ava Grace 2025 Oct 25, 00:00

Trump's Sudden Russia Policy Shift: Rubio's Influence and Implications

Emma Rose 2025 Oct 25, 00:00

Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty

Noah Lee 2025 Oct 25, 00:00

September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations

Emma Rose 2025 Oct 25, 00:00

Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge

Sophia Claire 2025 Oct 25, 00:00

Fund Managers Cautious in Q4: AI, Inflation, and Monetary Policy in Focus

Emma Rose 2025 Oct 25, 00:00

US Government Shutdown Threatens October Inflation Data Release

Sophia Claire 2025 Oct 24, 00:00

US-EU Relations: Russia Sanctions Unite Despite Trade Tensions

Emma Rose 2025 Oct 24, 00:00

BOJ Warns of Japan Stock Market Overheating, U.S. Trade Policy Risk

जानकारी

स्प्रेड

0.05

स्प्रेड (%)

0.8432 %

लीवरेज

1:10

ओवरनाइट ब्याज विक्रय

-0.0597 %

overnight_interest_sell

-0.0292 %

मुद्रा

USD

ट्रेडिंग घंटे

बाज़ार बंद है

सोमवार

13:31 - 19:59

मंगवार

13:31-19:59

बुधवार

13:31-19:59

गुरुवार

13:31-19:59

शुक्रवार

13:31-19:59

विश्लेषण और सांख्यिकी

खुला

---

पिछला बंद

---

52 सप्ताह उच्च/निम्न्च

--- – ---

बाज़ार आकार

850168576

बकाया शेयर

138916426

प्राप्ति की तिथि (आगे)

0000-00-00

लाभांश आय 

पूर्व-लाभांश तिथि

अग्रिम वार्षिक लाभांश दर 

0

अग्रिम वार्षिक लाभांश आय

0

EPS

-4.01

इस उपकरण के बारे में अधिक जानें

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

संबंधित उपकरण

संपत्ति
बेचें
खरीदें
(%) परिवर्तित करें

अब ट्रेड करें

अब ट्रेड करें

अब ट्रेड करें

अब ट्रेड करें
view_all_instruments

latest_education_articles

और दिखाएं
Trustpilot